Meningococcal vaccine group C conjugate - GlaxoSmithKline

Drug Profile

Meningococcal vaccine group C conjugate - GlaxoSmithKline

Alternative Names: MenC; MenC-CRM conjugate vaccine; Meningococcal C-CRM197 conjugate vaccine; Menjugate

Latest Information Update: 22 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Meningococcal group C infections

Most Recent Events

  • 01 Mar 2016 GlaxoSmithKline initiates a phase I trial for Meningococcal group C infections (In volunteers) in Germany (IM) (NCT02639351)
  • 31 Dec 2015 GlaxoSmithKline plans a phase I trial for Meningococcal group C infections in Germany (IM) (NCT02639351)
  • 07 Dec 2012 CTP push (NCT01434680) - 700206549
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top